Sunpharma gain 1.5 percent after the company got US Food and Drug Administration approval to sell a drug to treat Osteoporosis, a bone-weakening disease. Currently the drug, Ibandronate Sodium, is marketed by Roche under the brand name Bovina. Bovina generated an annual sales of USD 82 million in 2012. Currently, Sun Pharma is the only generic player to have final approval for this product.
BUY SUN PHARMA ABOVE 625.50 WITH AN INTRA DAY TARGET OF 633-637
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.